NCT02500849View on ClinicalTrials.gov

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 10, 2016

Primary Completion Date

August 24, 2026

Study Completion Date

August 24, 2026

Conditions
HIV
Interventions
GENETIC

SB-728mR-HSPC Infusion 3 days following busulfan conditioning

Trial Locations (5)

90035

UCLA CARE Center, Los Angeles

90069

Mills Clinical Research, Los Angeles

91010

City of Hope Medical Center, Duarte

94115

Quest Clinical Research, San Francisco

06850

Circle CARE Center, LLC, Norwalk

Sponsors

Collaborators (1)

Sangamo Therapeutics
All Listed Sponsors
collaborator

Sangamo Therapeutics

INDUSTRY

collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

City of Hope Medical Center

OTHER